A new ACG Clinical Guideline, Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes, is featured in the September issue of The American Journal of Gastroenterology. Key updates from the 2015 guideline include expanded use of multigene panel testing, newly characterized hereditary polyposis syndromes, recommendations for colonic polyposis of unknown etiology, and enhanced guidance on upper GI surveillance and cancer prevention. The issue also includes articles on mental health screening in inflammatory bowel disease (IBD), empirical antifungal therapy in acute-on-chronic liver failure, GLP-1s and esophageal cancer risk, and auricular (ear) acupressure for patients with insomnia and functional dyspepsia.
Access to any articles from this issue, or past issues, is available upon request. The College is also able to connect members of the press with study authors or outside experts who can comment on the articles.
Current Issue:
Nebokitug, an Anti-chemokine (C-C Motif) Ligand 24 Monoclonal Antibody, in Patients With Primary Sclerosing Cholangitis: A Phase 2 StudyAnti-CCL24 monoclonal antibody nebokitug was safe and well tolerated in patients with primary sclerosing cholangitis, with no new safety concerns after 48 weeks of follow-up. The study did not show significant improvements in liver tests or fibrosis measures across the overall population, though patients with moderate-to-advanced fibrosis experienced significant reductions in liver stiffness and promising changes in several fibrosis-related biomarkers.
The Risk of Hypertensive Disorders of Pregnancy in Inflammatory Bowel DiseaseA large retrospective cohort study of more than 45,000 pregnancies found that IBD was not associated with an increased overall risk of hypertensive pregnancy disorders, but it was associated with 65% higher risk of pre-eclampsia. Patients with IBD also had significantly higher risks of preterm delivery, small-for-gestational-age infants, and cesarean delivery compared to those without IBD.
Advance Access:
Curcumin Suppresses Growth of Recurrent Colorectal Adenoma After Endoscopic Resection: A Randomized, Double-Blind, Placebo-Controlled, Multicenter TrialIn a randomized, double-blind, placebo-controlled trial of 577 patients with previously removed colorectal adenomas, participants received either curcumin or placebo for two years to determine whether curcumin could prevent adenoma recurrence. Though curcumin did not significantly reduce the overall rate of recurrent adenomas, it significantly reduced the occurrence of larger adenomas (≥6 mm), lowered the number of these lesions, and was associated with smaller adenoma size overall.